Differential inhibition of prion propagation by enantiomers of quinacrine

Laboratory Investigation

Volumn 83, Issue 6, 2003, Pages 837-843

  Ryou, Chongsuk ^a   Legname, Giuseppe ^a,b   Peretz, David ^a,b   Craig, John C ^a   Baldwin, Michael A ^a,b   Prusiner, Stanley B ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ISOPROTEIN; MEPACRINE; PRION PROTEIN; PRION PROTEIN SC; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIPRION ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CELL SURVIVAL; CYTOTOXICITY; DRUG EFFICACY; DRUG STRUCTURE; ENANTIOMER; NEUROBLASTOMA CELL; NONHUMAN; PRION; PRION DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; RACEMIC MIXTURE; SCRAPIE; STEREOCHEMISTRY;

EID: 0038340656     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.LAB.0000074919.08232.A2     Document Type: Article

References (33)

1. Albert A (1960). Selective toxicity. New York: John Wiley & Sons.
2. Armored Medical Research Laboratory and Commission on Tropical Diseases (1946). Plasma quinacrine concentration as a function of dosage and environment. Arch Intern Med 78:64-107.
3. Army Malaria Research Unit (1946). Mepacrine in animal tissues. Ann Trop Med Parasitol 40:173-180.
4. Berliner RW, Earle DP, Taggart JV, Zubrod CG, Welch WJ, Conan NJ, Bauman E, Scudder ST, and Shannon JA (1948). Studies on the chemotherapy of the human malarias. J Clin Invest 27:98-107.
5. Blanchard KC and Schmidt LH' (1946). Chemical series of potential interest. In: Wiselogle FY, Wiselogle FY, editors. A survey of antimalarial drugs, 1941-1945. Ann Arbor: J. W. Edwards, 73-175.
6. Brocks DR and Jamali F (1995). Stereochemical aspects of pharmacotherapy. Pharmacotherapy 15:551-564.
7. Caspi S, Sasson SB, Taraboulos A, and Gabizon R (1998). The anti-prion activity of Congo red: Putative mechanism. J Biol Chem 273:3484-3489.
8. Caughey B and Race RE (1992). Potent inhibition of scrapie-associated PrP accumulation by Congo red. J Neurochem 59:768-771.
9. Collins SJ, Lewis V, Brazier M, Hill AF, Fletcher A, and Masters CL (2002). Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann Neurol 52:503-506.
10. Craig JC, Labelle B, and Ohnsorge U (1991). The absolute configuration of the enantiomers of 6-chloro-9-(4′-diethylamino-1′-methylbutyl)-amino-2- methoxyacridine (quinacrine). Chirality 3:436-437.
11. Crowe R and Burnstock G (1984). Quinacrine-positive neurones in some regions of the guinea-pig brain. Brain Res Bull 12:387-391.
12. Dearborn EH (1947). The distribution of quinacrine in dogs and in rabbits. J Pharmacol Exp Ther 91:174-177.
13. Dearborn EH, Kelsey FE, Oldham FK, and Geiling EMK (1943). Studies on antimaladals. J Pharmacol Exp Ther 78:120-126.
14. Dickinson AG, Fraser H, and Outram GW (1975). Scrapie incubation time can exceed natural lifespan. Nature 256:732-733.
15. Diringer H and Ehlers B (1991). Chemoprophylaxis of scrapie in mice. J Gen Virol 72:457-460.
16. Doh-ura K, Iwaki T, and Caughey B (2000). Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol 74:4894-4897.
17. Ehlers B and Diringer H (1984). Dextran sulphate 500 delays and prevents mouse scrapie by impairment of agent replication in spleen. J Gen Virol 65:1325-1330.
18. Findlay GM (1951). Recent advances in chemotherapy. Philadelphia: The Blakiston Company.
19. Fitzhugh OG, Nelson AA, and Calvery HO (1945). The chronic toxicity of quinacrine (atabrine). J Pharmacol Exp Ther 85:207-221.
20. Goodman LS and Gilman A (1955). The pharmacological basis of therapeutics. New York: Macmillan.
21. Hammick DL and Chambers WE (1945). Optical activity of excreted mepacrine. Nature 155:141.
22. Howroyd PC and Gee DJ (1985). The use of fluorescence microscopy and microfluorimetry to study the distribution of quinacrine in mice. Histochem J 17:13-21.
23. Hutt AJ and Tan SC (1996). Drug chirality and its clinical significance. Drugs 52:1-12.
24. Kimberlin RH and Walker CA (1983). The antiviral compound HPA-23 can prevent scrapie when administered at the time of infection. Arch Virol 78:9-18.
25. Korth C, May BCH, Cohen FE, and Prusiner SB (2001). Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci USA 98:9836-9841.
26. Peretz D, Williamson RA, Kaneko K, Vergara J, Leclerc E, Schmitt-Ulms G, Mehlhorn IR, Legname G, Wormald MR, Rudd PM, Dwek RA, Burton DR, and Prusiner SB (2001). Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 412:739-743.
27. Priola SA, Raines A, and Caughey WS (2000). Porphyrin and phthalocyanine antiscrapie compounds. Science 287:1503-1506.
28. Shannon JA, Earle DP, Brodie BB, Taggart JV, and Berliner RW (1944). The pharmacological basis for the rational use of Atabrine in the treatment of malaria. J Pharmacol Exp Ther 81:307-330.
29. Siegel H and Mushett CW (1944). Structural changes following administration of quinacrine hydrochloride. Arch Pathol 38:63-70.
30. Supattapone S, Nguyen H-OB, Cohen FE, Prusiner SB, and Scott MR (1999). Elimination of prions by branched polyamines and implications for therapeutics. Proc Natl Acad Sci USA 96:14529-14534.
31. Supattapone S, Wille H, Uyechi L, Safar J, Tremblay P, Szoka FC, Cohen FE, Prusiner SB, and Scott MR (2001). Branched polyamines cure prion-infected neuroblastoma cells. J Virol 75:3453-3461.
32. Tucker GT (2000). Chiral switches. Lancet 355:1085-1087.
33. Webster RV, Craig JC, Shyamala V, Kirby GC, and Warhurst DC (1991). Antimalarial activity of optical isomers of quinacrine dihydrochloride against chloroquine-sensitive and -resistant Plasmodium falciparum in vitro. Biochem Pharmacol 42(Suppl):225-227.